Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment

Digestive and Liver Disease

Volumn 42, Issue 2, 2010, Pages 110-114

  Sacco, F ^a   Spezzaferro, M ^a   Amitrano, M ^a   Grossi, L ^a   Manzoli, L ^a   Marzio, L ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Amoxicillin; Esomeprazole; First line therapy; H. pylori infection; Moxifloxacin

Indexed keywords

AMOXICILLIN; ESOMEPRAZOLE; MOXIFLOXACIN; RIFABUTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; APHTHOUS STOMATITIS; ARTICLE; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT FAILURE; UREA BREATH TEST; ANTIBIOTIC THERAPY; INFECTION CONTROL;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; AZA COMPOUNDS; BREATH TESTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; QUINOLINES; UREA; YOUNG ADULT;

EID: 73749088673     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.05.013     Document Type: Article

References (25)

1. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56 (2007) 772-781
2. Caselli M, Zullo A, Maconi G, et al. Cervia II Working Group Report 2006: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Working Group of the Cervia II Meeting. Dig Liver Dis 2007;39:782-9.
3. De Francesco V., Margiotta M., Zullo A., Hassan C., Troiani L., and Burattini O. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 144 (2006) 94-100
4. Boyanova L., Gergova G., Nikolov R., et al. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 60 (2008) 409-415
5. Marzio L., Coraggio D., Capodicasa S., Grossi L., and Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 11 (2006) 237-242
6. Amitrano M., Sacco F., Spezzaferro M., et al. H. pylori isolates from proximal and distal stomach of patients with H. pylori infection exhibit resistance and sensitivity to the same antibiotic. Gastroenterology 134 Suppl. 1 (2008) A335 [Abstract]
7. Toracchio S., and Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 35 (2003) 541-545
8. Gisbert J.P., Fernández-Bermejo M., Molina-Infante J., et al. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 26 (2007) 495-500
9. Antos D., Schneider-Brachert W., Bästlein E., et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 11 (2006) 39-45
10. Di Caro S., Ojetti V., Zocco M.A., et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 16 (2002) 527-532
11. Nista E.C., Candelli M., Zocco M.A., et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 21 (2005) 1241-1247
12. Bago P., Vcev A., Tomic M., Rozankovic M., Marusic M., and Bago J. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 119 (2007) 372-378
13. Sezgin O., Altintas E., Uçbilek E., Tombak A., and Tellioglu B. Low efficacy rate of moxifloxacin-containing Helicobacter pylori eradication treatment: in an observational study in a Turkish population. Helicobacter 12 (2007) 518-522
14. Kiliç Z.M., Köksal A.S., Cakal B., et al. Moxifloxacin plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci 53 (2008) 313-317
15. Armstrong D., Bennett J.R., Blum A.L., et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 111 (1996) 85-92
16. Toracchio S., Capodicasa S., Soraja D.B., Cellini L., and Marzio. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 37 (2005) 33-38
17. Gisbert J.P., Gisbert J.L., Marcos S., Olivares D., and Pajares J.M. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 22 (2005) 1041-1046
18. Woodford N., and Ellington M.J. The emergence resistance by mutation. Clin Microbiol Infect 13 (2007) 5-18
19. Perna F., Zullo A., Ricci C., Hassan C., Morini S., and Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 39 (2007) 1001-1005
20. Calvet X., Ducons J., Bujanda L., Bory F., Montserrat A., and Gisbert J.P. Seven vs ten-day of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 100 (2005) 1696-1701
21. BeyerJ, and Schellong S. Bilateral plantar tendinitis during levofloxacin therapy. Br J Clin Pharmacol 61 (2006) 609
22. Falagas M.E., Rafailidis P.I., and Rosmarakis E.S. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 29 (2007) 374-379
23. Rokkas T., Sechopoulos P., Robotis I., Margantinis G., and Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 104 (2009) 21-25
24. Navarro-Jarabo J.M., Fernández N., Sousa F.L., et al. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection. BMC Gastroenterol 7 (2007) 31
25. Bago J., Pevec B., Tomić M., Marusić M., Bakula V., and Bago P. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 121 (2009) 47-52